Associated Papers
An update on the monogenic causes of Parkinson's disease: Impact on patient stratification and personalised medicine.
Asmi S et al.
Ageing Research Reviews, 2026
The LRRK2 G2385R Exonic Variant: A Potential Genetic Disease Modifier of Multiple System Atrophy?
Kouki N et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2026
Association of LRRK2 p.A419V with Parkinson's Disease in East Asians and analysis of age at onset.
Lim KS et al.
Npj Parkinson's Disease, 2026
Protective or Pathogenic? Kinase activity and the neurodevelopmental origins of G2019S LRRK2-Associated Parkinson's disease.
Gatto EM et al.
Parkinsonism & Related Disorders, 2026
Effect of deep brain stimulation on early-onset Parkinson's disease with mutations in a Han Chinese Mainland population.
Chen S et al.
Bmc Neurology, 2026
Genetic insights from Parkinson disease in African and African admixed populations.
Rizig M et al.
Nature Reviews. Neurology, 2026
Rare but Relevant? Assessing Variants in Dystonia-Linked Genes in Parkinson's Disease.
Lange LM et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2026
Genetic analysis of LRRK2 variants in Han Chinese patients with Parkinson's disease.
Deng X et al.
Plos One, 2026
The Global Parkinson's Disease Genetics (GP2) Genome Browser.
Fang ZH et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Deciphering the PGC-1α-TFAM Axis in Parkinson's Disease (PD) - A Mechanism Approach Targeting Therapeutics for PD.
Iyer M et al.
Molecular Neurobiology, 2025
Bridging pleiotropic mechanisms in leprosy type-1 reactions and neurodegenerative diseases.
Fava VM et al.
Scientific Reports, 2025
LRRK2 as a Potential Disease-Modifying Target in Sporadic Parkinson's Disease.
Lang AE et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2025
E3 Ubiquitin Ligases: Structures, Biological Functions, Diseases, and Therapy.
Wang H et al.
Medcomm, 2025
Motor response in monogenic LRRK2 parkinson's disease after deep brain stimulation: A systematic review and meta-analysis.
Ar Rochmah M et al.
The Medical Journal of Malaysia, 2025
Soluble immune factor profiles in blood and CSF associated with LRRK2 mutations and Parkinson's disease.
Jaffery R et al.
Npj Parkinson's Disease, 2025
LRRK2 p.G2385R and p.R1628P variants in a multi-ethnic Asian Parkinson's Cohort: epidemiology and clinical insights.
Goh JW et al.
Npj Parkinson's Disease, 2025
Dysfunctional Alternative Polyadenylation Modifies the Penetrance of LRRK2 Variants in Parkinson's Disease.
Yang S et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2025
LRRK2 and the fragile synapse: a molecular prelude to Parkinson's disease?
Masotti B et al.
The Biochemical Journal, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Decreased SNCA expression in whole-blood RNA analysis of Parkinson's disease adjusting for neutrophils.
Xu KY et al.
Npj Parkinson's Disease, 2025
Large-scale genetic characterization of Parkinson's disease in the African and African admixed populations.
Akçimen F et al.
Brain : a Journal of Neurology, 2025
Hypoxia and TTR dysregulation in astrocytes from Parkinson's disease with a specific mitochondrial haplogroup: A single-cell analysis.
Wang J et al.
Neural Regeneration Research, 2025
The LRRK2 p.A419V variant associates with risk of Parkinson's disease in the East Asian population and an evaluation on age of onset.
Lim KS et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Clinical feature and alpha-synuclein level of restless legs syndrome with leucine-rich repeat kinase 2 encoding gene mutation.
Guo X et al.
Parkinsonism & Related Disorders, 2025
PPM1M, an LRRK2-counteracting, phosphoRab12-preferring phosphatase with a potential link to Parkinson's disease.
Chiang CY et al.
Cell Reports, 2025
14-3-3 binding maintains the Parkinson's associated kinase LRRK2 in an inactive state.
Martinez Fiesco JA et al.
Nature Communications, 2025
Therapeutic Targeting of Autosomal Parkinson's Disease by Modulation of Leucine-Rich Repeat Kinase 2 (LRRK2) Protein.
Hyderi Z et al.
Brain Research, 2025
Association of LRRK2 R1628P variant with Parkinson's disease in Kinh Vietnamese: a cross-sectional study.
Do MD et al.
Neurogenetics, 2025
The Global Landscape of Genetic Variation in Parkinson's disease: Multi-Ancestry Insights into Established Disease Genes and their Translational Relevance.
Lange LM et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Rare but Relevant: Assessing Variants in Dystonia-linked Genes in Parkinson's Disease.
Lange LM et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Strengths, Weaknesses, Opportunities, and Potential Threat Analysis of Targeting Leucine-Rich Repeat Kinase 2 for Parkinson's Disease Treatment: Status Quo and Quo Vadis.
Dang C et al.
Journal of Medicinal Chemistry, 2025
Leucine-Rich Repeat Kinase 2: Pathways to Parkinson's Disease.
Pfeffer SR et al.
Cold Spring Harbor Perspectives in Medicine, 2025
Functional Enrichment Analysis of Rare Mutations in Patients with Brain Arteriovenous Malformations.
Zholdybayeva E et al.
Biomedicines, 2025
Investigation of the Impact of Deep Brain Stimulation of the Subthalamic Nucleus on Parkinson Disease Patients with Genetic Risk Factors/Causes.
Wu S et al.
World Neurosurgery, 2025
Genomic landscape of paired primary and peritoneal metastatic lesions in gastric cancer highlights evolutionary dynamics and mutational drivers.
Li S et al.
Journal of Advanced Research, 2025
Assessment of common genetic variation in Alzheimer's and Parkinson's diseases reveals global distinction in population attributable risk.
Jones L et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
LRRK2 rare-variant per-domain genetic burden in Parkinson's Disease: association confined to the kinase domain.
Parlar SC et al.
Npj Parkinson's Disease, 2025
Population-Specific Differences in Pathogenic Variants of Genes Associated with Monogenic Parkinson's Disease.
Flores-Ocampo V et al.
Genes, 2025